Last reviewed · How we verify
Dornase Alfa Inhalant Solution [Pulmozyme]
Dornase Alfa Inhalant Solution [Pulmozyme] is a Recombinant enzyme Small molecule drug developed by University Hospital, Strasbourg, France. It is currently in Phase 3 development for Cystic fibrosis with FEV1 ≥40% predicted, Reduction of respiratory tract infections in cystic fibrosis patients.
Dornase alfa is a recombinant human deoxyribonuclease that cleaves extracellular DNA in airway secretions, reducing mucus viscosity and improving clearance.
Dornase alfa is a recombinant human deoxyribonuclease that cleaves extracellular DNA in airway secretions, reducing mucus viscosity and improving clearance. Used for Cystic fibrosis with FEV1 ≥40% predicted, Reduction of respiratory tract infections in cystic fibrosis patients.
At a glance
| Generic name | Dornase Alfa Inhalant Solution [Pulmozyme] |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | Recombinant enzyme |
| Target | Extracellular DNA (deoxyribonucleic acid) |
| Modality | Small molecule |
| Therapeutic area | Pulmonology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
In cystic fibrosis patients, neutrophil infiltration releases large amounts of DNA into the airways, which increases sputum viscosity and impairs mucociliary clearance. Dornase alfa enzymatically degrades this extracellular DNA, reducing sputum viscoelasticity and facilitating airway drainage. This improves lung function and reduces respiratory infections in CF patients.
Approved indications
- Cystic fibrosis with FEV1 ≥40% predicted
- Reduction of respiratory tract infections in cystic fibrosis patients
Common side effects
- Voice hoarseness
- Pharyngitis
- Laryngitis
- Chest pain
- Hemoptysis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dornase Alfa Inhalant Solution [Pulmozyme] CI brief — competitive landscape report
- Dornase Alfa Inhalant Solution [Pulmozyme] updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI
Frequently asked questions about Dornase Alfa Inhalant Solution [Pulmozyme]
What is Dornase Alfa Inhalant Solution [Pulmozyme]?
How does Dornase Alfa Inhalant Solution [Pulmozyme] work?
What is Dornase Alfa Inhalant Solution [Pulmozyme] used for?
Who makes Dornase Alfa Inhalant Solution [Pulmozyme]?
What drug class is Dornase Alfa Inhalant Solution [Pulmozyme] in?
What development phase is Dornase Alfa Inhalant Solution [Pulmozyme] in?
What are the side effects of Dornase Alfa Inhalant Solution [Pulmozyme]?
What does Dornase Alfa Inhalant Solution [Pulmozyme] target?
Related
- Drug class: All Recombinant enzyme drugs
- Target: All drugs targeting Extracellular DNA (deoxyribonucleic acid)
- Manufacturer: University Hospital, Strasbourg, France — full pipeline
- Therapeutic area: All drugs in Pulmonology / Respiratory
- Indication: Drugs for Cystic fibrosis with FEV1 ≥40% predicted
- Indication: Drugs for Reduction of respiratory tract infections in cystic fibrosis patients
- Compare: Dornase Alfa Inhalant Solution [Pulmozyme] vs similar drugs
- Pricing: Dornase Alfa Inhalant Solution [Pulmozyme] cost, discount & access